Form 8-K - Current report:
SEC Accession No. 0001193125-21-197924
Filing Date
2021-06-24
Accepted
2021-06-24 07:06:32
Documents
13
Period of Report
2021-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d136287d8k.htm   iXBRL 8-K 32469
2 EX-10.1 d136287dex101.htm EX-10.1 73714
  Complete submission text file 0001193125-21-197924.txt   244178

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20210623.xsd EX-101.SCH 2915
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20210623_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20210623_pre.xml EX-101.PRE 11423
6 EXTRACTED XBRL INSTANCE DOCUMENT d136287d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 211040570
SIC: 2834 Pharmaceutical Preparations